Denali Therapeutics Cash Flow Statement (2017-2026) | DNLI

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Cash Flow Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Operating Activities
Net Income (Quarter)	-60.69M	-84.59M	-75.26M	-66.50M	-58.79M	-103.30M	-98.68M	-109.78M	183.38M	-99.35M	-119.47M	-101.80M	-99.03M	-107.19M	-114.69M	-132.97M	-124.12M	-126.90M	-128.45M	-128.45M
Depreciation and Depletion (Quarter)
Share-based Compensation (Quarter)	21.14M	21.00M	22.09M	26.14M	23.94M	24.58M	25.19M	28.08M	26.57M	27.46M	25.99M	27.84M	25.10M	24.86M	25.08M	25.16M	25.39M	25.14M	23.95M	23.09M
Gains from Sales and Divestitures (Quarter)
Gains from Investment Securities (Quarter)	-0.00M					-0.05M	0.05M	0.00M		-0.00M	0.00M			1.18M	8.18M	4.36M	-7.38M	11.17M	-8.92M	-0.29M
Non-cash Items (Quarter)
Cash from Operations (Quarter)	-54.22M	-41.43M	-65.49M	-72.11M	-42.90M	-57.05M	-72.66M	-58.80M	-113.17M	-87.36M	-98.66M	-113.62M	-91.22M	-59.14M	-83.72M	-131.47M	-75.30M	-107.30M	-98.54M	-131.20M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles (Quarter)	-2.50M	-2.66M	-2.43M	-1.63M	-0.49M	0.69M	1.43M	7.85M	11.53M					0.40M	0.80M	0.89M	0.90M	0.90M	0.93M	0.92M
Depreciation & Amortization (CF) (Quarter)	2.20M	2.19M	2.10M	2.08M	2.07M	2.14M	4.11M	10.05M	2.29M	2.22M	2.18M	2.16M	1.94M	1.84M	1.85M	2.33M	3.04M	2.95M	2.88M	2.85M
Change in Working Capital
Change in Account Payables (Quarter)	2.38M	0.78M	-0.08M	1.25M	0.84M	1.90M	-1.72M	3.70M	4.77M	-3.96M	-2.08M	0.64M	3.89M	-4.37M	1.29M	-2.64M	2.60M	-4.07M	-3.41M	3.88M
Change in Accured Expenses (Quarter)	1.28M	6.49M	7.77M	-8.31M	5.87M	9.33M	4.03M	19.81M	-32.21M	0.73M	14.31M	2.32M	-20.82M	24.59M	-2.84M	-9.69M	-4.46M	1.89M	12.73M	-22.39M
Investing Activities
Capital Expenditures (Quarter)	0.23M	-0.20M	8.47M	0.11M	6.82M	6.05M	-11.52M	6.08M	2.56M	2.07M	2.23M	2.15M	4.79M	3.88M	-9.63M	5.08M	4.28M	-1.38M	1.52M	2.47M
Change in Acquisitions & Divestments (Quarter)	482.50M	293.06M	193.75M	250.50M	232.65M	144.34M	364.00M	433.79M	552.04M	601.12M	489.00M	383.12M	225.00M	198.00M	351.00M	161.75M	162.21M	107.08M	275.00M	220.00M
Cash from Investing Activities (Quarter)	97.54M	-53.01M	-40.75M	-117.88M	88.63M	15.42M	-127.56M	-92.72M	168.07M	100.91M	73.05M	-453.19M	98.57M	93.66M	172.21M	18.75M	157.94M	57.83M	20.77M	94.46M
Financing Activities
Other financing activities (Quarter)
Change in Capital Stock
Shares Issued (Quarter)	7.04M	3.31M	5.17M	1.46M	4.40M	5.15M	285.20M			13.12M	4.71M	1.02M	6.76M	5.46M	4.16M	0.59M	-0.59M		8.46M	12.37M
Misc.
Cash from Financing Activities (Quarter)	7.04M	3.31M	5.17M	1.46M	4.40M	5.15M	299.65M	1.60M	9.02M	2.49M	4.71M	500.27M	6.76M	-18.56M	-4.17M	-3.76M	1.62M	-0.78M	192.13M	219.04M
Change in Cash (Quarter)	50.36M	-91.13M	-101.08M	-188.52M	50.13M	-36.47M	99.43M	-149.91M	63.92M	16.04M	-20.91M	-66.53M	14.11M	15.96M	84.32M	-116.48M	84.26M	-50.24M	114.36M	182.30M
Free Cash Flow (Quarter)	-54.45M	-41.23M	-73.97M	-72.22M	-49.72M	-63.10M	-61.14M	-64.88M	-115.73M	-89.43M	-100.89M	-115.77M	-96.01M	-63.02M	-74.09M	-136.55M	-79.58M	-105.92M	-100.06M	-133.67M
Net Cash Flow (Quarter)	50.36M	-91.13M	-101.08M	-188.52M	50.13M	-36.47M	99.43M	-149.91M	63.92M	16.04M	-20.91M	-66.53M	14.11M	15.96M	84.32M	-116.48M	84.26M	-50.24M	114.36M	182.30M

Research Tools

Denali Therapeutics Cash Flow Statement (2017-2026) | DNLI

Create an account

Sign In

Reset Password